Harpoon Therapeutics Future Growth
Future criteria checks 2/6
Harpoon Therapeutics is forecast to grow earnings and revenue by 5.8% and 35.3% per annum respectively. EPS is expected to grow by 19.9% per annum. Return on equity is forecast to be -220.2% in 3 years.
Key information
5.8%
Earnings growth rate
19.9%
EPS growth rate
Biotechs earnings growth | 31.7% |
Revenue growth rate | 35.3% |
Future return on equity | -220.2% |
Analyst coverage | Good |
Last updated | 12 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 49 | -92 | -67 | -94 | 4 |
12/31/2025 | 31 | -72 | -54 | -64 | 6 |
12/31/2024 | 27 | -57 | -33 | -51 | 6 |
12/31/2023 | 40 | -27 | -16 | -40 | 6 |
9/30/2023 | 37 | -30 | -69 | -69 | N/A |
6/30/2023 | 47 | -40 | -77 | -77 | N/A |
3/31/2023 | 35 | -59 | -84 | -83 | N/A |
12/31/2022 | 32 | -68 | -90 | -89 | N/A |
9/30/2022 | 32 | -71 | -88 | -88 | N/A |
6/30/2022 | 23 | -76 | -84 | -84 | N/A |
3/31/2022 | 21 | -75 | -129 | -129 | N/A |
12/31/2021 | 24 | -117 | -122 | -122 | N/A |
9/30/2021 | 27 | -107 | -121 | -120 | N/A |
6/30/2021 | 26 | -103 | -114 | -113 | N/A |
3/31/2021 | 23 | -99 | -10 | -9 | N/A |
12/31/2020 | 17 | -50 | -9 | -9 | N/A |
9/30/2020 | 12 | -53 | 39 | 40 | N/A |
6/30/2020 | 10 | -55 | 40 | 43 | N/A |
3/31/2020 | 8 | -55 | -11 | -8 | N/A |
12/31/2019 | 6 | -56 | -6 | -3 | N/A |
9/30/2019 | 5 | -51 | -46 | -43 | N/A |
6/30/2019 | 4 | -42 | -41 | -39 | N/A |
3/31/2019 | 4 | -36 | -33 | -32 | N/A |
12/31/2018 | 5 | -27 | -28 | -27 | N/A |
9/30/2018 | 4 | -23 | -9 | -8 | N/A |
12/31/2017 | 1 | -17 | -1 | 2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 5HTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 5HTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 5HTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 5HTA's revenue (35.3% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: 5HTA's revenue (35.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 5HTA is forecast to be unprofitable in 3 years.